跳到正文
原文
Endpoints News 生物医药· Maggie Fick·· 6 天前AI 评分35

Argenx 花费数十亿美元推进Vyvgart

Argenx is spending billions to push beyond Vyvgart

AI 导读

Argenx 公司新任 CEO Karen Massey 在任六个月期间,已监督完成了两项合计价值约 34 亿美元的收购,旨在推动Vyvgart的发展。

正文

Six months in­to her term as CEO of rare dis­ease drug­mak­er ar­genx, Karen Massey has over­seen two ac­qui­si­tions worth a com­bined po­ten­tial of about $3.4 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news